Drugs / Phospholipovit
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05742022 | Jan 2016 → Jun 2018 | hyperlipidemia, combined, 2 | Institute of Biomedical Chemistry, Russia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phospholipovit | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05742022 ↗ |
| Modality | Other / unclassified | “the "Phospholipovit" - the aqueous medium of nanoemulsion of phospholipids” NCT05742022 ↗ |
| Route | Oral | “500 mg orally 2 times a day, for 12 weeks” NCT05742022 ↗ |